From: Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer
Variable | N | % |
---|---|---|
All | 149 | 100.0 |
T-stage | Â | Â |
1 | 105 | 70.5 |
> 1 | 44 | 29.5 |
N-stage | Â | Â |
0 | 91 | 61.1 |
> 1 | 58 | 38.9 |
Grade | Â | Â |
1 and 2 | 95 | 63.8 |
3 | 54 | 36.2 |
Histology | Â | Â |
IDC | 128 | 85.9 |
Other | 21 | 14.1 |
Hormone receptor status | Â | Â |
Negative | 19 | 12.8 |
Positive | 130 | 87.2 |
HER2 status | Â | Â |
Negative | 127 | 85.2 |
Amplified | 22 | 14.8 |
Ki 67 (cut-off 20%) | Â | Â |
Low | 92 | 61.7 |
High | 57 | 38.3 |
Lymphovascular invasion | Â | Â |
Present | 35 | 23.5 |
Absent | 114 | 76.5 |
Baseline CTC | Â | Â |
CTC Epithelial | Â | Â |
Negative | 133 | 89.3 |
Positive | 16 | 10.7 |
CTC EMT | Â | Â |
Negative | 126 | 84.6 |
Positive | 23 | 15.4 |
CTC Any | Â | Â |
Negative | 113 | 75.8 |
Positive | 36 | 24.2 |